肝移植术后早期并发症的危险因素分析

解恩博; 轩凤慧; 孙晓东; 孙大伟; 吕国悦

doi:10.3969/j.issn.1001-5256.2018.06.030

肝移植术后早期并发症的危险因素分析

DOI: 10.3969/j.issn.1001-5256.2018.06.030

1. 吉林大学白求恩第一医院肝胆胰外一科
2. 通辽市奈曼旗第一中学校医院

详细信息

中图分类号: R657.3
计量
- 文章访问数: 1713
- HTML全文浏览量: 40
- PDF下载量: 516
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-25
- 出版日期: 2018-06-20

An analysis of risk factors for early complications after liver transplantation

First Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University

摘要

摘要:
目的研究影响肝移植术后早期并发症的相关危险因素,以期改善患者预后。方法收集2011年9月-2017年4月于吉林大学白求恩第一医院肝移植中心接受原位肝移植术的147例肝移植患者的临床资料。根据早期并发症的有无分为无并发症组（n=11）和并发症组（n=136）。收集其可能发生术后早期并发症的相关因素,包括供体因素（年龄、供受体血型是否相符）,受体因素[包括性别、年龄、原发病、MELD评分、AST、ALT、Alb、PLT、Hb、纤维蛋白原、TBil、肌酐、PLT/Alb比值（PAR）、中性粒细胞/淋巴细胞比值（NLR）],术中因素（包括冷缺血时间、热缺血时间、术中出血量、无肝期时间）,术后因素（包括术后即时、12 h、24 h、48 h、72 h AST和ALT）。符合正态分布的计量资料2组间比较采用t检验;不符合正态分布的计量资料2组间比较采用Mann-Whitney U检验;多因素分析采用向后LR法logistic回归分析。结果单因素分析显示,MELD评分（t=-3.86,P=0.002）、Alb（t=2.19,P=0.049）、PLT（Z=467.00,P=0.039）、PAR（Z=5...
- 肝移植 /
- 手术后并发症 /
- 危险因素
Abstract:
Objective To investigate the risk factors for early complications after liver transplantation and to improve the prognosis. Methods The clinical data of 147 patients who underwent orthotopic liver transplantation in the Hepatic Transplantation Center of The First Hospital of Jilin University from September 2011 to April 2017 were retrospectively analyzed. According to the presence or absence of early complications after surgery, these patients were divided into non-complication group (n = 11) and complication group (n = 136) . The possible factors associated with early complications after surgery were collected, including donor factors (age and whether the blood type of the donor matches that of the recipient) , recipient factors (sex, age, primary disease, Model for End-Stage Liver Disease [MELD]score, aspartate aminotransferase [AST], alanine aminotransferase[ALT], albumin [Alb], platelet [PLT], hemoglobin [Hb], fibrinogen, total bilirubin, creatinine, PLT/Alb ratio [PAR], and neutrophil/lymphocyte ratio [NLR]) , intraoperative factors (cold ischemia time, warm ischemia time, intraoperative blood loss, and duration of anhepatic phase) , and postoperative factors (AST and ALT immediately and 12, 24, 48, and 72 hours after operation) . The clinical data were analyzed to investigate the association between these factors and early complications.The t test was used for comparison of normally distributed continuous data; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data. The chi-square test was used for comparison of categorical data. Backward logistic regression was used for multivariate analysis. Results MELD score (t =-3. 86, P = 0. 002) , Alb (t = 2. 19, P = 0. 049) , PLT (Z = 467. 00, P = 0. 039) , PAR (Z = 500. 00, P = 0. 068) , fibrinogen (t = 1. 80, P = 0. 096) , TBil (Z =-1. 98, P = 0. 047) , preoperative AST (Z = 417. 00, P =0. 015) , and preoperative ALT (Z = 501. 50, P = 0. 070) were associated with postoperative complications. PAR and preoperative AST were independent risk factors for early complications (odds ratio [OR]= 3. 84, 95% confidence interval [CI]: 1. 03-14. 34, P < 0. 05; OR =0. 25, 95% CI: 0. 07-0. 94, P < 0. 05) . The 147 patients were divided into high-PAR group (PAR ≥3 × 109/g; n = 55) and low-PAR group (PAR < 3 × 109/g; n = 92) ; PAR was associated with postoperative vascular and biliary complications (χ2= 2. 87, P = 0. 090;χ2= 3. 54, P = 0. 060) . The 147 patients were divided into normal preoperative AST group (AST < 40 U/L; n = 93) and abnormal preoperative AST group (AST ≥40 U/L; n = 54) ; preoperative AST level was associated with postoperative pleural effusion (χ2= 3. 03, P =0. 082) . Conclusion Fibrinogen, PLT, Alb, TBil, PAR, MELD score, and preoperative AST and ALT are associated with the development of early complications after liver transplantation, and PAR and preoperative AST are independent risk factors for early complications.To improve the prognosis and postoperative survival, these factors, particularly PAR, should be fully assessed for the liver transplantation recipient before operation, and specific interventions should be provided accordingly.
- liver transplantation /
- postoperative complications /
- risk factors

HTML全文

参考文献(31)

[1]SHI YH, TIAN MX, FAN J.Recommendations for EASL clinical practice guidelines:liver transplantation (2015) [J].J Clin Hepatol, 2016, 31 (3) :429-431. (in Chinese) 史颖弘, 田孟鑫, 樊嘉.《欧洲肝病学会肝移植临床实践指南 (2015年) 》推荐意见[J].临床肝胆病杂志, 2016, 31 (3) :429-431.

[2]AZEVEDO LD, STUCCHI RS, ATAíDE EC.Assessment of causes of early death after twenty years of liver transplantation.[J].Transplant Proc, 2013, 45 (3) :1116-1118.

[3]DAI CL, YIN YE, LI H, et al.Significance of various detection methods in diagnosis of cytomegalovirus infection[J].Chin J Lab Diag, 2010, 14 (12) :2058-2059. (in Chinese) 戴春来, 尹艳娥, 李恒, 等.各种检测方法在巨细胞病毒感染诊断中的意义[J].中国实验诊断学, 2010, 14 (12) :2058-2059.

[4]CHEN XB, XU MQ.Primary graft dysfunction after liver transplantation[J].Hepatobiliary Pancreat Dis Int, 2014, 13 (2) :125-137.

[5]European Association for the Study of the Liver.EASL clinical practice guidelines:Liver transplantation[J].J Hepatol, 2016, 64 (2) :433-485.

[6]KOCHHAR G, PARUNGAO JM, HANOUNEH IA, et al.Biliary complications following liver transplantation[J].World J Gastroenterol, 2013, 19 (19) :2841-2846.

[7] WANG JY, LIAO EY, HUANG CX, et al.Internal medicine[M].Beijing:People's Medical Publishing House, 2013:662. (in Chinese) 王吉耀, 廖二元, 黄从新, 等.内科学[M].北京:人民卫生出版社, 2013:662.

[8]ZHOU L, PAN LC, SHI XJ, et al.Research advances in multicenter study on the role of the Model for End-Stage Liver Disease evaluation system in the selection of liver transplantation recipients[J].Organ Transplant, 2017, 8 (2) :174-178. (in Chinese) 周林, 潘立超, 史宪杰, 等.MELD评价体系对肝移植受者选择的多中心临床研究进展[J].器官移植, 2017, 8 (2) :174-178.

[9]SABATE A, DALMAU A.Fibrinogen:a clinical update on liver transplantation[J].Transplant Proc, 2015, 47 (10) :2925-2928.

[10]PORTE RJ, BLAUW E, KNOT EA, et al.Role of the donor liver in the origin of platelet disorders and hyperfibrinolysis in liver transplantation[J].J Hepatol, 1994, 21 (4) :592-600.

[11]JALAN R, SCHNURR K, MOOKERJEE RP, et al.Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality[J].Hepatology, 2009, 50 (2) :555-564.

[12]SHIRAI Y, SHIBA H, HARUKI K, et al.Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection[J].Anticancer Res, 2017, 37 (2) :787-793.

[13]POROWSKI D, WIRKOWSKA A, HRYNIEWIECKA E, et al.Liver failure impairs the intrahepatic elimination of interleukin-6, tumor necrosis factor-alpha, hepatocyte growth factor, and transforming growth factor-beta[J].Biomed Res Int, 2015, 2015:934065.

[14]ALEXANDRAKIS MG, PASSAM FH, MOSCHANDREA IA, et al.Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis[J].Am J Clin Oncol, 2003, 26 (2) :135-140.

[15]GASTACA M.Biliary complications after orthotopic liver transplantation:A review of incidence and risk factors[J].Transplant Proc, 2012, 44 (6) :1545-1549.

[16]FREEMAN RB Jr, WIESNER RH, HARPER A, et al.The new liver allocation system:Moving toward evidence-based transplantation policy[J].Liver Transpl, 2002, 8 (9) :851-858.

[17] WANG XM, PENG CH, YAN JQ, et al.Relationship between Meld score and the perioperative complications and mortality after orthtopic liver transplantation[J].Chin J Organ Transplant, 2007, 28 (2) :105-107. (in Chinese) 王小明, 彭承宏, 严佶祺, 等.Meld评分与肝移植围手术期并发症及死亡率的相关性[J].中华器官移植杂志, 2007, 28 (2) :105-107.

[18]CHEN W, YI YX, ZHANG HB, et al.Evaluation effect of three scoring systems in the prediction of short-term outcomes following liver transplantation.[J].Chin J Hepatobiliary Surg, 2014, 20 (8) :557-561. (in Chinese) 陈威, 易永祥, 张海斌, 等.三种评分系统预测肝移植短期预后的效果评价[J].中华肝胆外科杂志, 2014, 20 (8) :557-561.

[19]WIEDERKEHR JC, IGREJA MR, NOGARA MS, et al.Analysis of survival after primary liver transplantation:Multivariate analysis of 155 cases in a single center[J].Transplant Proc, 2010, 42 (2) :511-512.

[20]SCHLEGEL A, LINECKER M, KRON P, et al.Risk assessment in high-and low-meld liver transplantation[J].Am J Transplant, 2017, 17 (4) :1050-1063.

[21]HALLDORSON JB, RAYHILL S, BAKTHAVATSALAM R, et al.Serum alkaline phosphatase and bilirubin are early surrogate markers for ischemic cholangiopathy and graft failure in liver transplantation from donation after circulatory death[J].Transplant Proc, 2015, 47 (2) :465-468.

[22]PLEVAK DJ, SOUTHORN PA, NARR BJ, et al.Intensive-care unit experience in the Mayo liver transplantation program:The first100 cases[J].Mayo Clinic Proceedings, 1989, 64 (4) :433-445.

[23]SHAHEEN AA, MYERS RP.Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C related fibrosis a systematic review[J].Hepatology, 2007, 46 (3) :912.

[24]EI SERAFY MA, KASSEM AM, OMAR H, et al.APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis:Systematic review and meta-analysis[J].Arab J Gastroenterol, 2017, 18 (2) :51-57.

[25]JAIN A, REYES J, KASHYAP R, et al.Long-term survival after liver transplantation in 4, 000 consecutive patients at a single center[J].Ann Surg, 2000, 232 (4) :490-500.

[26]DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury.II.Recommendations for use of laboratory tests in screening, diagnosis, and monitoring[J].Clin Chem, 2000, 46 (12) :2050-2068.

[27]BAHDE R, SPIEGEL HU.Hepatic ischaemia-reperfusion injury from bench to bedside[J].Br J Surg, 2010, 97 (10) :1461-1475.

[28]ARDITE E, RAMOS C, RIMOLA A, et al.Hepatocellular oxidative stress and initial graft injury in human liver transplantation[J].J Hepatol, 1999, 31 (5) :921-927.

[29]GIANNINI EG, TESTA R, SAVARINO V.Liver enzyme alteration:A guide for clinicians[J].CMAJ, 2005, 172 (3) :367-379.

[30]SEETO RK, FENN B, ROCKEY DC.Ischemic hepatitis:Clinical presentation and pathogenesis[J].Am J Med, 2000, 109 (2) :109-113.

[31]DETRY O, DEROOVER A, MEURISSE N, et al.Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol progrankme[J].Br J Surg, 2014, 101 (7) :784-792.

施引文献

资源附件(0)

访问统计